Formula Growth Ltd. purchased a new position in CeriBell, Inc. (NASDAQ:CBLL – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 31,000 shares of the company’s stock, valued at approximately $603,000.
Several other large investors have also added to or reduced their stakes in CBLL. Strs Ohio purchased a new position in CeriBell during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of CeriBell during the 3rd quarter valued at about $33,000. CWM LLC increased its position in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period.
CeriBell Trading Down 0.3%
Shares of NASDAQ CBLL opened at $23.37 on Friday. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The firm has a 50-day moving average of $20.00 and a 200 day moving average of $19.32. The stock has a market cap of $896.94 million, a P/E ratio of -13.28 and a beta of 0.81.
Analysts Set New Price Targets
Several analysts have commented on the stock. Canaccord Genuity Group raised their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, BTIG Research raised their target price on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $22.40.
Get Our Latest Analysis on CeriBell
Insider Transactions at CeriBell
In related news, CRO Joseph S. Manni sold 1,361 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $32,691.22. Following the sale, the executive owned 55,956 shares in the company, valued at $1,344,063.12. This represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Scott Blumberg sold 1,521 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total value of $36,534.42. Following the transaction, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at approximately $3,521,332. This trade represents a 1.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 382,067 shares of company stock worth $8,025,866. Company insiders own 17.70% of the company’s stock.
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
- Five stocks we like better than CeriBell
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell, Inc. (NASDAQ:CBLL – Free Report).
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
